Dr. Jill F. Rodila, MD

Dr. Rodila practices at Cornea & Refractive Consultants of the Palm Beaches, PA in Palm Beach Gardens, Florida.

Dr. Rodila's NPI, 1568487676, was assigned on July 12, 2006. Dr. Rodila graduated from University of Illinois College of Medicine - Chicago in 1999. Dr. Rodila holds Florida license ME87752.

Dr. Rodila's primary practice is Cornea & Refractive Consultants of the Palm Beaches, PA, at 11020 Rca Center Dr, Palm Beach Gardens, FL 33410 in Palm Beach County. The practice phone is (561) 624-7878.

Dr. Rodila's primary practice is Cornea & Refractive Consultants of the Palm Beaches, PA in Palm Beach Gardens, Florida. Dmand AI also links Dr. Rodila to 2 medical groups, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rodila practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Rodila's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Rodila is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Rodila is licensed in Florida.

Dmand AI lists cataract, cataract surgery with lens implant, eyelid inflammation, glaucoma, secondary membranaous cataract surgery and vitreous eye degeneration among the conditions Dr. Rodila treats.

CMS data shows 475 Medicare services from Dr. Rodila across 9 procedure codes in 2024, for 89 Medicare patients. Medicare paid $61,204 for them.

CMS counts 89 Medicare patients who saw Dr. Rodila in 2024. The largest group is 75 to 84, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rodila's median patient age at 77, with 45% women.

In 2024, Dr. Rodila wrote 154 Medicare Part D claims for 47 patients. 59% of them were for generic drugs. CMS names the drug for 110 of them, across 4 drugs with 11 or more claims each, at $3,459 in total drug cost. In 2023, CMS named 57 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Rodila for performance year 2024, reported as part of a group. Dr. Rodila accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 43 procedures of cataract surgery by Dr. Rodila, more than 60% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Rodila in 2006. Dr. Rodila's most frequent co-authors are Eduardo Alfonso, MD, William W. Culbertson, MD and Kendall E. Donaldson, MD.

Dmand AI links Dr. Rodila to 1 clinical trial. Conditions studied include Cataract and Lens Diseases.

CMS Open Payments shows 23 general payments to Dr. Rodila from 16 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Johnson & Johnson Surgical Vision, Inc. paid the most, $170.

Dr. Rodila graduated from University of Illinois College of Medicine - Chicago in 1999.

Dr. Rodila is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.